Form 4 for ENTX Entera Bio Ltd.

Accepted 2026-08-07 16:21:09 ET · period of report 2026-08-07 · accession 0001178913-26-003954 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-08-07 16:21	2026-08-07	ENTX	Ellis Sean	Dir	A - Grant	$0.00	+20.0K	208.1K	+11%	$0
D	2026-08-07 16:21	2026-08-07	ENTX	Ellis Sean	Dir	A - Grant	$0.00	+40.0K	40.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares, par value NIS 0.0000769 per share	2026-08-07	A	A	20,034	$0.00	208,132	D	—	—	(F1) The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.
2	Derivative	Stock Option (right to buy)	2026-08-07	A	A	40,000	$0.00	40,000	D	$1.37 · 2026-08-07 to 2036-05-07	40,000 Ordinary Shares, par value NIS 0.0000769 per share	(F2) Represents a grant of fully vested options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026.